China’s New Regs For Infant Formula Makers Look To Raise Quality Of Local Industry, Level Playing Field
This article was originally published in PharmAsia News
Executive Summary
Similar to its investigations of the pharma industry, China has stepped up oversight of pricing and compliance in the infant formula industry. To tighten supervision, CFDA has released several new rules on manufacturing and marketing that raise standards and prohibit promotion of formula to medical institutions.